Insights & Perspectives

Filter by

Therapeutic Area / Research

Year Starting

Year Ending

Search Insights:
Showing 1 to 10 of 356
Filter by: Unfiltered

Blog Post | Dec 12, 2014

The immunotherapy wave has finally hit the shores of the breast cancer landscape

Read more | Share

Newsletter | Dec 11, 2014

Kantar Health Catalyst, December 2014

Download the Catalyst newsletter to read our latest insights on privacy issues in Big Data, the oncology pipeline, and patient research.

Read more | Share

Case Study | Dec 9, 2014

Using gamification techniques to improve a multinational online quantitative survey

A multi-national pharmaceutical company increased engagement on a long-running physician survey by applying gamification techniques. The gamified survey brought new insights and actionable recommendations for our client that ultimately influenced the client's brand strategy.

Read more | Share

Blog Post | Dec 9, 2014

The battlefield extends into hematologic malignancies – continuing the race between PD-1-targeted therapeutics

Oncology Conference Insight: ASH 2014 --- Immune checkpoints in the Programmed Death -1 (PD-1) pathway have critical roles in balancing the co-stimulatory and co-inhibitory signals that regulate human self-tolerance and control the amplitude and duration of T‑cell responses. PD-1 is a key immune checkpoint receptor expressed on activated T-cells. Binding of PD-1 to its ligand (PD-L1) results in suppression of the immune response and tumor cells can manipulate this critical pathway to elude attack by tumor-infiltrating T-cells.

Read more | Share

Blog Post | Dec 9, 2014

Adcetris continues to advance outcomes in relapsed/refractory Hodgkin’s lymphoma

Oncology Conference Insight: ASH 2014 --- Hodgkin’s Lymphoma (HL) represents one of the more successful stories in oncology. The four-regimen combination of adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) is standard of care for newly-diagnosed patients, and prognosis is excellent for patients who respond, demonstrating a five-year overall survival of approximately 80%.

Read more | Share

Blog Post | Dec 8, 2014

Something to ASPIRE to? Kyprolis + RevDex combination in relapsed/refractory multiple myeloma

Oncology Conference Insight: ASH 2014 --- Proteasome inhibitors and immunomodulators (IMiDs) are the mainstay of therapy for multiple myeloma. For years, treatment has relied on Velcade® (bortezomib, Millennium/Takeda/Johnson & Johnson) and Revlimid® (lenalidomide, Celgene) as part of first-line and second-line therapy, usually in sequence. Recently, two advances have changed this paradigm.

Read more | Share

Infographic | Dec 1, 2014

Impact of Ebola on Social Media

After the case of the nurse infected with Ebola in Spain, numerous comments have appeared on social media, especially on Twitter. Different public and political organizations shared their opinions online regarding the way the Spanish government has dealt with this issue.

Datasheet | Nov 20, 2014

Biosimilars in China: Market Access and Barriers

This report provides insights into the opportunities and barriers in the Chinese biosimilars market, how to maximise these opportunities and reduce the threats to reap return-on-investment.

Read more | Share

White Paper | Nov 19, 2014

Key Findings from the 2014 European Society of Medical Oncology (ESMO) Annual Meeting

This issue of Oncology Conference Insight highlights significant information presented at ESMO 2014, which took place September 26-30 in Madrid, Spain. Our goal is to provide our clients with the latest information presented at oncology meetings.

Read more | Share

Infographic | Nov 10, 2014

Protecting our future - Changing habits to guard against diabetes

382 million people are living with diabetes worldwide. By 2035, 592 million people or one person in 10 will have the disease. 316 million people are currently at high risk of developing type 2 diabetes, and that is expected to increase to almost 500 million within a generation.

Page  < 123456789 >